ArticleMolecular neurobiology2026
Epigenetic Dysregulation of the Wnt/β-Catenin Pathway via FTO-m6A in the mPFC Contributes to Autism-Like Behaviors.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Post-transcriptional modifications of RNA, particularly m6A methylation, are emerging as critical epigenetic regulators of neurodevelopment and behavior. Although the RNA demethylase, fat mass and obesity-associated (FTO) protein has been implicated in autism spectrum disorder (ASD), the precise mRNA targets and downstream molecular pathways through which it governs behavior remain unclear. Here, we identify a significant upregulation of FTO in the medial prefrontal cortex (mPFC) of BTBR mice, a well-established ASD model. Targeted knockdown of Fto in the mPFC successfully ameliorates core ASD-like behavioral deficits. Mechanistically, m6A methylome analysis reveals Ctnnb1 (encoding β-catenin) as a direct functional substrate of FTO. FTO-mediated m6A demethylation of Ctnnb1 mRNA enhances its expression, driving aberrant hyperactivation of the Wnt/β-catenin signaling pathway. Translating these molecular insights, systemic pharmacological inhibition of the Wnt/β-catenin pathway partially rescues the behavioral phenotypes in BTBR mice. Importantly, in vivo fiber photometry revealed that this pharmacological rescue is accompanied by the restoration of impaired calcium dynamics in mPFC excitatory neurons during novel object recognition. Together, these findings elucidate a novel epitranscriptomic mechanism whereby the mPFC FTO-m6A-Ctnnb1 axis drives ASD-like phenotypes. Furthermore, they provide preclinical evidence that targeting this specific epigenetic and signaling pathway represents a highly viable pharmacological strategy for ASD intervention.
Indexed as
Identifiers
42343060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.